260 related articles for article (PubMed ID: 27783223)
1. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence.
Nuño Solinís R; Arratibel Ugarte P; Rojo A; Sanchez Gonzalez Y
Infect Dis Ther; 2016 Dec; 5(4):491-508. PubMed ID: 27783223
[TBL] [Abstract][Full Text] [Related]
2. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.
Smith-Palmer J; Cerri K; Valentine W
BMC Infect Dis; 2015 Jan; 15():19. PubMed ID: 25596623
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
[TBL] [Abstract][Full Text] [Related]
5. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
6. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
You MW; Kim KW; Shim JJ; Pyo J
J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
Alem SA; Eletreby R; Abdellatif Z; Ramadan A; Nagy A; AbdAllah M; Elsharkawy A; Fouad R; Esmat G; Tantawi O
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e746-e752. PubMed ID: 34231522
[TBL] [Abstract][Full Text] [Related]
8. Impact of direct acting antivirals (DAA) on neurologic disorders in chronic hepatitis C.
Chemello L; Cavalletto L; Ferrari S; Monaco S
Minerva Gastroenterol (Torino); 2021 Sep; 67(3):234-243. PubMed ID: 34672486
[TBL] [Abstract][Full Text] [Related]
9. The impact of hepatitis C virus outside the liver: Evidence from Asia.
Younossi ZM; Tanaka A; Eguchi Y; Lim YS; Yu ML; Kawada N; Dan YY; Brooks-Rooney C; Negro F; Mondelli MU
Liver Int; 2017 Feb; 37(2):159-172. PubMed ID: 27748564
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
11. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study.
Shiha G; Mousa N; Soliman R; Nnh Mikhail N; Adel Elbasiony M; Khattab M
J Viral Hepat; 2020 Jul; 27(7):671-679. PubMed ID: 32050037
[TBL] [Abstract][Full Text] [Related]
12. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
16. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response.
Hallager S; Ladelund S; Christensen PB; Kjær M; Thorup Roege B; Grønbæk KE; Belard E; Barfod TS; Madsen LG; Gerstoft J; Tarp B; Krarup HB; Weis N
Clin Epidemiol; 2017; 9():501-516. PubMed ID: 29123424
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China.
Xie Q; Xuan JW; Tang H; Ye XG; Xu P; Lee IH; Hu SL
World J Hepatol; 2019 May; 11(5):421-441. PubMed ID: 31183003
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort.
Pereira Guedes T; Fragoso P; Lemos C; Garrido M; Silva J; Falcão D; Maia L; Moreira T; Manuel Ferreira J; Pedroto I
GE Port J Gastroenterol; 2020 Apr; 27(3):149-159. PubMed ID: 32509920
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
